bpc-157 clinical trials trial humans human kpv bpc 157 tb500 dihexa human status 2026 SCOPE 2026, Simplified Patient Recruitment Management, AI Powered Clinical Trial Finders Research Breakdown on BPC-157 bpc 157 human clinical trial

Pre-Blend Dose Assessment (10 units / 0.10 mL daily) Component GHK-Cu Per-dose from Blend ~1.67 mg Typical Standalone 1-2 mg daily Assessment In range Component BPC-157 Per-dose from Blend ~0.33 mg Typical Standalone 0.25-0.5 mg daily Assessment In range Component TB-500 Per-dose from Blend ~0.33 mg Typical Standalone 2-5 mg per injection, 2x/week Assessment Below standalone injury range The 5:1:1 blend is convenience- and skin-focused

This does NOT mean FDA approval

medRxiv 2023

For the bigger picture, read how supervised peptide therapy at Perfect B in Doral is structured and how it supports safe, monitored use of peptides